Medically reviewed by Matthew Wosnitzer, MD Most prostate cancers eventually stop responding to androgen deprivation therapy ...

Gonadorelin, a synthetic analog of the gonadotropin-releasing hormone (GnRH), has garnered attention for its intriguing ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.